Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI crystal ball: can machine learning forecast stroke recovery?

NCT ID NCT07750015

Knowledge-focused Sponsor: Dr. med. Alexander Salerno, MD-PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study is developing and testing computer models, called FORECAST-PC, to predict how well people will recover 90 days after a stroke caused by a blockage in the back of the brain. The models use information from when a patient arrives at the hospital and 24 hours later to estimate their chances of a good or poor outcome. The goal is to give doctors a better tool to guide treatment decisions and set realistic expectations for patients and their families.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Machine learning prediction models (FORECAST-PC)
What this could lead to
If successful, this could give doctors a reliable tool to predict recovery after stroke treatment, helping guide care decisions and set realistic expectations for patients and families.
What could go wrong
The models are new and need validation in different patient groups. They may not be accurate for everyone, and the study does not test a treatment, so it cannot directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

732 people

The number who actually took part.

Started

Jan 2015

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population comprises adult patients (older than 18 years) presenting with acute ischemic stroke (AIS) attributed to a radiologically confirmed posterior circulation large vessel occlusion. These individuals were treated at 14 international comprehensive stroke centers, with initial participation rooted in the European EVA-TRISP network. Patients were included if they were selected for endovascular thrombectomy (EVT) within 24 hours of the last known well time, regardless of whether they received prior intravenous thrombolysis (IVT) or were managed via mothership or drip-and-ship pathways. Participants were required to have a pre-stroke modified Rankin Scale (mRS) of 0 to 3. The cohort explicitly excludes patients whose strokes occurred in-hospital, patients treated beyond the 24-hour window, and patients treated prior to 2015.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Presentation with acute ischemic stroke (AIS) attributed to a radiologically confirmed posterior circulation occlusion * Selected for Endovascular Thrombectomy (EVT) according to the treating physician * Pre-stroke modified Rankin Scale (mRS) 0-3 * EVT initiated or attempted within 24-hours of the last known well (LKW) time * Includes cases with/without prior intravenous thrombolysis (IVT), mothership, and drip-and-ship pathways Exclusion Criteria: * EVT carried out beyond 24 hours from stroke onset * EVT performed secondarily after in-hospital worsening or stroke recurrence * In-hospital strokes (to avoid the confounding influence of prior systemic comorbidities and the acute event that necessitated initial admission) * Missing primary outcome data * Inconsistencies between descriptive dependence status and raw pre-stroke mRS * Stroke cases occurring prior to 2015 (to account for major changes in endovascular treatment techniques)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral infarction cerebrovascular disorder posterior cerebral artery infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral infarction Cerebrovascular disorders Posterior ischemic stroke

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, 1010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.